A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO).

Decker, T., Overkamp, F., Rösel, S., Nusch, A., Göhler, T., Indorf, M., Sahlmann, J., Trarbach, T., 2017.

BMC Cancer 17(1), 499. doi:10.1186/s12885-017-3492-1

Studie: PASO; Indikation: Mammakarzinom; Jahr: 2017; Veranstaltung: -; Journal: BMC Cancer

iOMEDICO AG
Hanferstraße 28
79108 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com